EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer.

Studies which found a slight significance in patient response [ 22 ] or prognosis [ 23 ], or like our cohort did not show any significance of the EGFR status on clinical outcome [ 24 ], along with our results, might be subject for a meta-analysis; however, it is unlikely that the large variation in patient response and patient survival would rely on the R521K polymorphism as a single determining factor.

also in 68 other papers